Literature DB >> 30477890

Outcomes of patients with Guillain Barre Syndrome - Experience from a tertiary care hospital of a developing Asian country and review of regional literature.

Sarah H Siddiqui1, Tahira H Siddiqui2, Masood U Babar3, Adeel Khoja4, Sara Khan5.   

Abstract

Outcomes of Guillain Barre Syndrome (GBS), particularly those require mechanical ventilation have been reported from a number of Asian countries, albeit, scarcely from Pakistan. We conducted this study to determine the short-term outcomes of GBS and compare the results of mechanically ventilated and non-ventilated patients. Case records of patients admitted with GBS during 2011-2016 at a large tertiary care centre of Pakistan were retrospectively reviewed. 216 patients satisfying inclusion criteria were included. Patients were divided into 2 groups based on requirement of MV (MV and non-MV group). Short term outcomes were assessed by Modified Rankin Scale (MRS) at discharge, 2 weeks and 3 months and comparison done between MV and non-MV group. Outcome based on MRS score is categorized as good (MRS = 0-3) or poor (MRS = 4-6). Requirement for MV was noted in 24.5%. MV patients had severe weakness at presentation, longer length of hospital stay (LOS) and higher frequency of in-hospital complications. Overall mortality was 7.9%. Good outcomes at discharge and at 3 months were noted in significantly higher frequency in non-MV group (50.3% and 93.2% respectively) as compared to MV group (11.3% and 33.3% respectively). In MV group, increasing age, areflexia and longer LOS stay were found as independent predictors of poor outcome. Overall outcomes of GBS in our population are comparable to both regional and international studies. However, poor outcomes in MV group are seen in higher frequency in our study. Increasing age, areflexia and longer LOS may predict poor outcome in MV patients.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Guillain–Barré syndrome; Mechanical ventilation; Modified Rankin Scale; Mortality; Outcome

Mesh:

Year:  2018        PMID: 30477890     DOI: 10.1016/j.jocn.2018.11.031

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  3 in total

1.  Mortality and disability reported after immunoglobulins or plasmapheresis treatment of Guillain-Barré syndrome.

Authors:  Edinson Dante Meregildo-Rodriguez; Victor Hugo Bardales-Zuta
Journal:  Infez Med       Date:  2021-12-10

2.  Therapeutic Plasma Exchange as a Treatment for Autoimmune Neurological Disease.

Authors:  Ivana Nieto-Aristizábal; Álvaro J Vivas; Pablo Ruiz-Montaño; Cristian C Aragón; Iván Posso-Osorio; Jairo Quiñones; Julián Alejandro Rivillas; Gabriel J Tobón
Journal:  Autoimmune Dis       Date:  2020-07-31

3.  Effect of Electromyographic Biofeedback Therapy on Muscle Strength Recovery in Children with Guillain-Barré Syndrome.

Authors:  Qianqian Liu; Jianhua Xue; Pingping Zhao; Yue Ling; Suzhe Liu; Yakun Du; Ning Han; Mingxia Liu; Wei Di
Journal:  J Healthc Eng       Date:  2021-12-23       Impact factor: 2.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.